Like any other tool, understanding the right problem to apply it to is the difference between success and failure. Addressing a problem is never just about technology; it’s always about people, processes, and technology.
Genesis Therapeutics recently joined the growing list of AI-powered drug discovery startups receiving venture funding this year. The company closed a $200 million Series B financing round, taking its total funding to date to more than $280 million.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Pharma players, now more than ever, need a new and powerful tool to differentiate their products. We believe the next decade of transformation is digital.
Inertia is a barrier as is the traditional split between the clinical and the data-driven spheres of drug development. While smaller firms have an edge in bridging the gap, big pharma will eventually get there, said panelists at the INVEST conference session.
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company's technology and growth of its commercial use cases.